GBR 8383Alternative Names: GBR8383
Latest Information Update: 19 Jan 2017
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Antineoplastics
- Mechanism of Action OX40 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Jan 2017 Preclinical trials in Cancer in India before January 2017 (Glenmark Pharmaceuticals pipeline, January 2017)